The present meta-analysis highlights MPO as a promising biomarker of cancer-therapy-related cardiotoxicity, whereas the available evidence does not yet consistently support a beneficial role for galectin-3, potentially due to significant heterogeneity. This evidence concerns the gene MPO and cancer.